Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men

Bibliographic Details
Main Author: Anderson, Peter L.
Publication Date: 2012
Other Authors: Glidden, David V., Liu, Albert, Buchbinder, Susan, Lama, Javier R., Guanira, Juan Vicente, Mcmahan, Vanessa, Bushman, Lane R., Casapía, Martín, Montoya-Herrera, Orlando, Veloso, Valdiléa G., Mayer, Kenneth H., Chariyalertsak, Suwat, Schechter, Mauro, Bekker, Linda-Gail, Kallas, Esper Georges, Grant, Robert M.
Format: Article
Language: eng
Source: Repositório Institucional da FIOCRUZ (ARCA)
DOI: 10.1126/scitranslmed.3004006
Download full: https://arca.fiocruz.br/handle/icict/30002
Summary: For the iPrEx Study Team.
id CRUZ_27e22072a62d349bbdd6a19b01d8ff51
oai_identifier_str oai:arca.fiocruz.br:icict/30002
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Anderson, Peter L.Glidden, David V.Liu, AlbertBuchbinder, SusanLama, Javier R.Guanira, Juan VicenteMcmahan, VanessaBushman, Lane R.Casapía, MartínMontoya-Herrera, OrlandoVeloso, Valdiléa G.Mayer, Kenneth H.Chariyalertsak, SuwatSchechter, MauroBekker, Linda-GailKallas, Esper GeorgesGrant, Robert M.2018-11-12T17:44:03Z2018-11-12T17:44:03Z2012ANDERSON, Peter L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine, v. 4, n. 151, p. 1-17, Sept. 2012.1946-6234https://arca.fiocruz.br/handle/icict/3000210.1126/scitranslmed.30040061946-6242For the iPrEx Study Team.NIH R21MH085598 (A.L), UO1 AI084735 (P.L.A.), RO1 AI062333 (R.M.G), and UO1 AI064002 (R.M.G), UL1 RR024131.University of Colorado. Denver, Aurora, USA.University of California. San Francisco, CA, USA.San Francisco Department of Public Health. HIV Research Section. San Francisco, CA, USA.University of California. San Francisco, CA, USA / San Francisco Department of Public Health. HIV Research Section. San Francisco, CA, USA.Investigaciones Medicas en Salud. Lima, Peru / Asociación Civil Impacta Salud y Educación. Lima, Peru.Asociación Civil Impacta Salud y Educación. Lima, Peru.Gladstone Institute of Virology and Immunology. San Francisco, CA, USA.University of Colorado. Denver, Aurora, USA.Asociación Civil Selva Amazónica. Iquitos, Maynas, Peru.Fundación Ecuatoriana Equidad. Guayaquil, Guayas, Ecuador.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Brown University. Providence, RI, USA / Fenway Health. Fenway Institute. Boston, MA, USA.Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.Universidade Federal do Rio de Janeiro. Hospital Escola São Francisco de Assis. Projeto Praça Onze. Rio de Janeiro, RJ, Brasil.University of Cape Town. Desmond Tutu HIV Centre and Department of Medicine. Cape Town, South Africa.Universidade de São Paulo. Faculdade de Medicina. Divisão de Imunologia Clínica e Alergia. São Paulo, SP, Brasil / Instituto de Investigação em Imunologia. São Paulo, SP, Brasil.University of California. San Francisco, CA, USA / Gladstone Institute of Virology and Immunology. San Francisco, CA, USA.Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We evaluated drug concentrations among men who have sex with men in a substudy of the iPrEx trial (1). In this randomized placebo-controlled trial, daily oral doses of emtricitabine/tenofovir disoproxil fumarate were used as pre-exposure prophylaxis (PrEP) in men who have sex with men. Drug was detected less frequently in blood plasma and in viable cryopreserved peripheral blood mononuclear cells (PBMCs) in HIV-infected cases at the visit when HIV was first discovered compared with controls at the matched time point of the study (8% versus 44%; P < 0.001) and in the 90 days before that visit (11% versus 51%; P < 0.001). An intracellular concentration of the active form of tenofovir, tenofovir-diphosphate (TFV-DP), of 16 fmol per million PBMCs was associated with a 90% reduction in HIV acquisition relative to the placebo arm. Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week. Prophylactic benefits were observed over a range of doses and drug concentrations, suggesting ways to optimize PrEP regimens for this population.engEmtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with meninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleEmtricitabine-tenofovir concentrationsHIV-1Men who have sex with meninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://arca.fiocruz.br/bitstreams/940b2336-4d25-4bed-b4d2-70e102a1d704/download586c046dcfeef936e32f0323bb9a47c0MD51falseAnonymousREADORIGINALEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdfEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdfapplication/pdf1120733https://arca.fiocruz.br/bitstreams/5aba64b4-5d84-413f-9734-3ef4cd1bfe69/download909f60bb92a3e4a355ab39bc32c849c2MD52trueAnonymousREADTEXTEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdf.txtEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdf.txtExtracted texttext/plain46878https://arca.fiocruz.br/bitstreams/94a463c1-35e0-4a16-ad1b-177a954155cc/download350db80d3d46b13ff5d0bfcd799a5e67MD56falseAnonymousREADTHUMBNAILCapa_page-0001.jpgCapa_page-0001.jpgimage/jpeg1045803https://arca.fiocruz.br/bitstreams/c16e14ba-cf75-4720-97df-3f754f6bb612/downloadd8ddd8ef1272f95f8a03de2080c9d5a6MD54falseAnonymousREADEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdf.jpgEmtricitabine-tenofovir exposure_Valdilea_Veloso_INI_LapClin-AIDS_2012.pdf.jpgGenerated Thumbnailimage/jpeg5837https://arca.fiocruz.br/bitstreams/f560977f-f09d-4c7b-b774-1856ad1e8865/download888bf0e210fcbba27b83e76a19ba26deMD57falseAnonymousREADicict/300022025-07-30 02:46:12.636open.accessoai:arca.fiocruz.br:icict/30002https://arca.fiocruz.brRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352025-07-30T05:46:12Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)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
dc.title.none.fl_str_mv Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
title Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
spellingShingle Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
Anderson, Peter L.
Emtricitabine-tenofovir concentrations
HIV-1
Men who have sex with men
title_short Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
title_full Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
title_fullStr Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
title_full_unstemmed Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
title_sort Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
author Anderson, Peter L.
author_facet Anderson, Peter L.
Glidden, David V.
Liu, Albert
Buchbinder, Susan
Lama, Javier R.
Guanira, Juan Vicente
Mcmahan, Vanessa
Bushman, Lane R.
Casapía, Martín
Montoya-Herrera, Orlando
Veloso, Valdiléa G.
Mayer, Kenneth H.
Chariyalertsak, Suwat
Schechter, Mauro
Bekker, Linda-Gail
Kallas, Esper Georges
Grant, Robert M.
author_role author
author2 Glidden, David V.
Liu, Albert
Buchbinder, Susan
Lama, Javier R.
Guanira, Juan Vicente
Mcmahan, Vanessa
Bushman, Lane R.
Casapía, Martín
Montoya-Herrera, Orlando
Veloso, Valdiléa G.
Mayer, Kenneth H.
Chariyalertsak, Suwat
Schechter, Mauro
Bekker, Linda-Gail
Kallas, Esper Georges
Grant, Robert M.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Anderson, Peter L.
Glidden, David V.
Liu, Albert
Buchbinder, Susan
Lama, Javier R.
Guanira, Juan Vicente
Mcmahan, Vanessa
Bushman, Lane R.
Casapía, Martín
Montoya-Herrera, Orlando
Veloso, Valdiléa G.
Mayer, Kenneth H.
Chariyalertsak, Suwat
Schechter, Mauro
Bekker, Linda-Gail
Kallas, Esper Georges
Grant, Robert M.
dc.subject.en.none.fl_str_mv Emtricitabine-tenofovir concentrations
HIV-1
Men who have sex with men
topic Emtricitabine-tenofovir concentrations
HIV-1
Men who have sex with men
description For the iPrEx Study Team.
publishDate 2012
dc.date.issued.fl_str_mv 2012
dc.date.accessioned.fl_str_mv 2018-11-12T17:44:03Z
dc.date.available.fl_str_mv 2018-11-12T17:44:03Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ANDERSON, Peter L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine, v. 4, n. 151, p. 1-17, Sept. 2012.
dc.identifier.uri.fl_str_mv https://arca.fiocruz.br/handle/icict/30002
dc.identifier.issn.none.fl_str_mv 1946-6234
dc.identifier.doi.none.fl_str_mv 10.1126/scitranslmed.3004006
dc.identifier.eissn.none.fl_str_mv 1946-6242
identifier_str_mv ANDERSON, Peter L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine, v. 4, n. 151, p. 1-17, Sept. 2012.
1946-6234
10.1126/scitranslmed.3004006
1946-6242
url https://arca.fiocruz.br/handle/icict/30002
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://arca.fiocruz.br/bitstreams/940b2336-4d25-4bed-b4d2-70e102a1d704/download
https://arca.fiocruz.br/bitstreams/5aba64b4-5d84-413f-9734-3ef4cd1bfe69/download
https://arca.fiocruz.br/bitstreams/94a463c1-35e0-4a16-ad1b-177a954155cc/download
https://arca.fiocruz.br/bitstreams/c16e14ba-cf75-4720-97df-3f754f6bb612/download
https://arca.fiocruz.br/bitstreams/f560977f-f09d-4c7b-b774-1856ad1e8865/download
bitstream.checksum.fl_str_mv 586c046dcfeef936e32f0323bb9a47c0
909f60bb92a3e4a355ab39bc32c849c2
350db80d3d46b13ff5d0bfcd799a5e67
d8ddd8ef1272f95f8a03de2080c9d5a6
888bf0e210fcbba27b83e76a19ba26de
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1839716480997916672

Similar Items